-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Durvalumab is a selective, high-affinity human immunoglobulin G1 monoclonal antibody (mAb) that blocks programmed cell death ligand-1 (PD-L1) and programmed cell death-1 (PD-1) Binding to CD80 enables T cells to recognize and kill tumor cells
Durvalumab significantly improved overall survival in patients with unresectable stage III non-small cell lung cancer and was progression-free after concurrent chemoradiotherapy (cCRT)
Patients with composite inclusion criteria were randomized (1:1:1) to receive either Durvalumab monotherapy or Durvalumab+Oleclumab or Durvalumab+Monalizumab consolidation therapy within 42 days of cCRT for up to 12 months, stratified by histology
The objective response rates were 17.
In conclusion, compared with Durvalumab monotherapy, the two combination regimens can relatively improve the objective response rate and prolong the progression-free survival without increasing safety issues
Compared with Durvalumab monotherapy, both combination regimens can relatively improve objective response rate and prolong progression-free survival without increasing safety issues.
Original source:
Original source:Roy S.
Roy S.
Herbst, et al.
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer.
J Clin Oncol.
https://ascopubs.
org/doi/full/10.
1200/JCO.
22.
00227
Leave a comment here